[{"address1": "80 Guest Street", "address2": "Suite 601", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "617 500 8099", "website": "https://www.compasstherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Dr. Thomas J. Schuetz M.D., Ph.D.", "age": 63, "title": "Chief Executive Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 835875, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Vered  Bisker-Leib MBA, Ph.D.", "age": 53, "title": "Advisor", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 719000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Shin J.D.", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan  Anderman J.D.", "title": "Senior Vice President, General Counsel & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Anna  Gifford", "title": "Communications Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Minori  Rosales M.D., Ph.D.", "age": 61, "title": "Senior VP & Head of Clinical Development", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karin  Herrera B.A.", "title": "VP & Head of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Kranz Ph.D.", "title": "VP and Head of Chemistry Manufacturing & Controls", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.45, "open": 3.51, "dayLow": 3.37, "dayHigh": 3.66, "regularMarketPreviousClose": 3.45, "regularMarketOpen": 3.51, "regularMarketDayLow": 3.37, "regularMarketDayHigh": 3.66, "beta": 0.976, "forwardPE": -8.928336, "volume": 603878, "regularMarketVolume": 603878, "averageVolume": 1349367, "averageVolume10days": 1187900, "averageDailyVolume10Day": 1187900, "bid": 2.58, "ask": 3.68, "bidSize": 200, "askSize": 1600, "marketCap": 465050816, "fiftyTwoWeekLow": 0.765, "fiftyTwoWeekHigh": 4.08, "priceToSalesTrailing12Months": 547.1186, "fiftyDayAverage": 2.2188, "twoHundredDayAverage": 1.62324, "currency": "USD", "enterpriseValue": 336526400, "floatShares": 99288473, "sharesOutstanding": 137588992, "sharesShort": 2748956, "sharesShortPriorMonth": 2210789, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.02, "heldPercentInsiders": 0.18168, "heldPercentInstitutions": 0.71294, "shortRatio": 1.02, "shortPercentOfFloat": 0.028199999, "impliedSharesOutstanding": 137588992, "bookValue": 1.006, "priceToBook": 3.3598409, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -47757000, "trailingEps": -0.35, "forwardEps": -0.51, "enterpriseToRevenue": 395.913, "enterpriseToEbitda": -6.137, "52WeekChange": 0.8648648, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CMPX", "underlyingSymbol": "CMPX", "shortName": "Compass Therapeutics, Inc.", "longName": "Compass Therapeutics, Inc.", "firstTradeDateEpochUtc": 1617629400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "2da7fead-7fe9-351a-a396-4dd759234d3a", "messageBoardId": "finmb_266166780", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.38, "targetHighPrice": 32.0, "targetLowPrice": 4.0, "targetMeanPrice": 11.125, "targetMedianPrice": 9.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 135402000, "totalCashPerShare": 0.984, "ebitda": -54834000, "totalDebt": 6877000, "quickRatio": 30.544, "currentRatio": 31.838, "totalRevenue": 850000, "debtToEquity": 4.969, "revenuePerShare": 0.006, "returnOnAssets": -0.21712999, "returnOnEquity": -0.32004002, "grossProfits": 850000, "freeCashflow": -31852500, "operatingCashflow": -48047000, "grossMargins": 1.0, "operatingMargins": -65.22824, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]